{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=27", "query": { "condition": "Phase II", "page": 27 }, "page_size": 10 }, "pagination": { "page": 27, "page_size": 10, "total_count": 21412, "total_pages": 2142, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=28&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=26&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T16:53:10.918Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00667017", "title": "RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "RFT5-dgA immunotoxin", "type": "BIOLOGICAL" }, { "name": "fluorescence activated cell sorting", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 1, "start_date": "2008-11-07", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2018-12-14", "last_synced_at": "2026-11-15T16:53:10.918Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00667017" }, { "nct_id": "NCT07935317", "title": "A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Tersolisib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2026-12", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-11-13", "last_synced_at": "2026-11-15T16:53:10.918Z", "location_count": 9, "location_summary": "Los Alamitos, California • Lakewood, Colorado • Atlanta, Georgia + 6 more", "locations": [ { "city": "Los Alamitos", "state": "California" }, { "city": "Lakewood", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07935317" }, { "nct_id": "NCT00002889", "title": "Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "flutamide", "type": "DRUG" }, { "name": "goserelin", "type": "DRUG" }, { "name": "leuprolide acetate", "type": "DRUG" }, { "name": "low-LET photon therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "MALE", "summary": "30 Years and older · Male only" }, "enrollment_count": 180, "start_date": "1997-05", "completion_date": "2009-06", "has_results": false, "last_update_posted_date": "2023-08-18", "last_synced_at": "2026-11-15T16:53:10.918Z", "location_count": 12, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002889" }, { "nct_id": "NCT04339738", "title": "Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Skin Angiosarcoma", "Skin Radiation-Related Angiosarcoma", "Visceral Angiosarcoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "FDG-Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2020-11-04", "completion_date": "2027-01-21", "has_results": true, "last_update_posted_date": "2026-11-13", "last_synced_at": "2026-11-15T16:53:10.918Z", "location_count": 170, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 120 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04339738" }, { "nct_id": "NCT07552558", "title": "Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "HPV-Negative Squamous Cell Carcinoma" ], "interventions": [ { "name": "Hypofractionated Stereotactic Body Radiotherapy (SBRT)", "type": "RADIATION" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Ficerafusp alfa", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "BIOLOGICAL", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2026-11-30", "completion_date": "2034-01-31", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-15T16:53:10.918Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07552558" }, { "nct_id": "NCT03575325", "title": "Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoid Leukemia", "Acute Lymphoblastic Leukemia", "Refractory Acute Lymphoblastic Leukemia", "Relapsed Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "CPX-351", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2018-10-11", "completion_date": "2023-09-14", "has_results": true, "last_update_posted_date": "2024-12-12", "last_synced_at": "2026-11-15T16:53:10.918Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03575325" }, { "nct_id": "NCT05907291", "title": "Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Congenital Adrenal Hyperplasia", "Classic Congenital Adrenal Hyperplasia" ], "interventions": [ { "name": "atumelnant (CRN04894)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Crinetics Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "16 Years to 75 Years" }, "enrollment_count": 38, "start_date": "2023-07-03", "completion_date": "2025-08-22", "has_results": true, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-11-15T16:53:10.918Z", "location_count": 8, "location_summary": "Pasadena, California • Ann Arbor, Michigan • Minneapolis, Minnesota + 5 more", "locations": [ { "city": "Pasadena", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Morehead City", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05907291" }, { "nct_id": "NCT03434418", "title": "A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "osimertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2018-06-30", "completion_date": "2022-10-12", "has_results": true, "last_update_posted_date": "2023-10-17", "last_synced_at": "2026-11-15T16:53:10.918Z", "location_count": 3, "location_summary": "Durham, North Carolina • Columbus, Ohio • Pittsburgh, Pennsylvania", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03434418" }, { "nct_id": "NCT04781374", "title": "Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Prostate Adenocarcinoma", "Castration-resistant Prostate Cancer", "Prostate Cancer", "Prostate Cancer Metastatic" ], "interventions": [ { "name": "Neratinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 0, "start_date": "2021-05-21", "completion_date": "2021-09-24", "has_results": false, "last_update_posted_date": "2023-07-11", "last_synced_at": "2026-11-15T16:53:10.918Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04781374" }, { "nct_id": "NCT00935090", "title": "3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [], "conditions": [ "Brain and Central Nervous System Tumors", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "3'-deoxy-3'-[18F]fluorothymidine", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2009-09", "completion_date": "2027-04-04", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-11-15T16:53:10.918Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00935090" } ] }